Table II.
Univariate competing risk regression models for recurrence-free survival and cancer-specific survival (HR = hazard ratio).
| RFS | CSS | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | |
| Synchronous disease | 1.39 | 0.88, 2.20 | 0.2 | 1.34 | 0.47, 3.81 | 0.6 |
| Metastases at RCC diagnosis | 1.38 | 0.85, 2.26 | 0.2 | 0.82 | 0.23, 2.96 | 0.8 |
| Age at metastasectomy (per 10 years) | 0.74 | 0.59, 0.94 | 0.012 | 0.95 | 0.59, 1.52 | 0.8 |
| Time from nephrectomy to metastasis (per year) | 0.95 | 0.90, 0.99 | 0.023 | 0.99 | 0.91, 1.08 | 0.8 |
| Time from metastasis to metastasectomy (per year) | 1.00 | 0.97, 1.03 | >0.9 | 0.96 | 0.90, 1.03 | 0.3 |
| Multiple tumors removed at metastasectomy | 1.95 | 1.26, 3.03 | 0.003 | 0.93 | 0.38, 2.27 | 0.9 |
| Maximum tumor size at metastasectomy (cm) | 1.05 | 0.99, 1.11 | 0.080 | 1.18 | 1.07, 1.29 | 0.001 |
| Sarcomatoid histology | 1.81 | 0.74, 4.40 | 0.2 | 3.70 | 1.09, 12.62 | 0.037 |
| KPS (per 10 patients) | 0.98 | 0.94, 1.02 | 0.3 | 1.00 | 0.95, 1.05 | >0.9 |
| Metastasectomy site | ||||||
| Adrenal | Ref. | - | 0.14 | - | - | - |
| Liver | 1.10 | 0.48, 2.52 | - | - | - | |
| Lung | 1.55 | 0.93, 2.58 | - | - | - | |
| Pancreas | 0.68 | 0.32, 1.48 | - | - | - | |
| Thyroid | 0.91 | 0.31, 2.70 | - | - | - | |